Revenue
2020
2021
2022
2023
2024
2025
Gensight Biologics S.a. (SIGHT)
Price€0.1114Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | €1,000 | €1.5M | €1.3M | €2.6M | €5.3M | €4.4M |
| Research & development | €6.4M | €12.4M | €19.4M | €19.3M | €22.9M | €22.4M |
| Operating expenses | €11.1M | €18.4M | €32.7M | €32.7M | €35.8M | €32.4M |
| Operating income | −€11.1M | −€15.8M | −€29.7M | −€27.8M | −€28.1M | −€24.9M |
| Operating margin | −1,105,500.00% | −1,054.20% | −2,343.80% | −1,078.04% | −533.09% | −567.46% |
| EBITDA | −€8.7M | −€14.8M | −€27.5M | −€26.8M | −€27.2M | −€24.0M |
| EBITDA margin | −868,800.00% | −983.60% | −2,171.82% | −1,036.95% | −515.50% | −546.38% |
| Net income | −€12.0M | −€14.0M | −€26.2M | −€27.6M | −€28.6M | −€34.0M |
| Net profit margin | −1,203,600.00% | −933.40% | −2,069.46% | −1,069.91% | −542.40% | −774.12% |
| Basic EPSper basic share | -€0.08 | -€0.15 | -€0.54 | -€0.60 | -€0.63 | -€0.97 |
| Diluted EPSper diluted share | -€0.08 | -€0.15 | -€0.54 | -€0.60 | -€0.63 | -€0.97 |
Owners
Reported shareholders and owner groups
15.20%of company shares
Sofinnova Partners SASSource updated Oct 6, 2026
View holders
| Holder | Ownership |
|---|---|
| 15.20%Oct 6, 2026 | |
| 12.70%Oct 6, 2026 | |
| 8.40%Oct 6, 2026 | |
| 6.80%Oct 6, 2026 | |
| 6.70%Oct 6, 2026 | |
| 1.60%Oct 6, 2026 | |
| 0.20%Oct 6, 2026 | |
| 0.10%Oct 6, 2026 |
These Euronext company-profile figures report shares in the company's capital. Named holders and owner groups are shown as published; free float, treasury shares, and unspecified holders are excluded from the colored segments.
Gray completes the 100% scale; it is not an estimate of other owners.
Source: Euronext / Cofisem ↗Checked Oct 21, 2026
Community posts
GenSight advances LUMEVOQ manufacturing transfer to Catalent
GenSight ($SIGHT) said an engineering batch of GS010/LUMEVOQ at Catalent was produced as planned, with viral genome concentration meeting target specifications. Preparations have begun for a GMP-standard batch to supply special-access progr ...
